A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

NCT05257265 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

459

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

DRUG: Centanafadine Hydrochloride
OTHER: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.